Abstract

Introduction: The high proliferative potential of triple negative breast cancer (TNBC) determines the importance of intensifying neoadjuvant chemotherapy regimens. Patients and methods: 80 patients (pts) with locally advanced TNBC (stages IIIA, IIIB, IIIC) were included in a nonrandomized single-arm phase II study. All pts received neoadjuvant chemotherapy: doxorubicin 40 mg/m2 IV, paclitaxel 160 mg/m2 IV, cisplatin 50 mg/m2 IV; all drugs were administered on the 1st day. It was planned to conduct 8 courses with an interval of 2 weeks (with colony-stimulating factors) followed by surgical treatment and pathological assessment. The primary end point was the rate of pathological complete response (pCR); the second end points were 5-year overall survival (OS), disease-free survival (DFS) and toxicity. Statistical hypothesis: it was expected that the use of a new intensified regimen of neoadjuvant chemotherapy would increase the incidence of pCR from 40% to 60%. Given the level of type 1 error (α = 0,05) and type 2 error (β = 0,2), 77 pts had to be included in the study. Under these conditions, the power of the study was 80%. Results: the rate of pCR was 62.5% (95% CI 50,9–73,1); 5-year OS – 74%, 5-year DFS – 69%. The main toxicity was: anemia (98.7% pts, including gr. 3 – 37,5% pts); neutropenia (85.0% pts, including gr. 3–4 – 57,5% pts; febrile neutropenia – 3,7% pts); nausea (100% pts, including gr. 3 – 3,8% pts), polyneuropathy (50.0% pts, including gr. 3 – 8,7% pts). Conclusion: the rate of pCR was 62.5%, which corresponds to the statistical hypothesis with the stated frequency of this indicator of more than 60%. High efficacy and controlled toxicity allow us to consider the studied regimen as one of the possible options for neoadjuvant chemotherapy for locally advanced TNBC

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call